Immunocore Holdings (IMCR) Research & Development (2023 - 2026)

Immunocore Holdings has disclosed Research & Development across 4 years of filings, most recently posting $61.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $61.1 million, up 8.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.5 million (up 26.39% YoY), and the FY2025 annual result was $274.9 million, up 23.73% from the prior year.
• Research & Development came in at $61.1 million for Q1 2026 at Immunocore Holdings, down from $78.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $78.8 million in Q4 2025 to a low of $36.6 million in Q1 2023.
• The 4-year median for Research & Development is $56.5 million (2025), against an average of $55.5 million.
• Across the five-year window, Research & Development soared 57.11% in 2024 and slipped 1.72% in 2025, its largest moves.
• Immunocore Holdings' Research & Development stood at $45.6 million in 2023, then soared by 33.55% to $60.8 million in 2024, then rose by 29.53% to $78.8 million in 2025, then fell by 22.47% to $61.1 million in 2026.
• The last three Research & Development figures came in at $61.1 million (Q1 2026), $78.8 million (Q4 2025), and $70.6 million (Q3 2025), per Business Quant data.